All study participants included in the current analysis are participants of the prospective genetic and phenotypic determinants of BP and other cardiovascular risk factors (GAPP) study. Detailed information Abstract-Hypertension and diabetes mellitus are highly correlated, but the underlying mechanisms are only partly understood.
levated blood pressure (BP) and dysglycemia are highly prevalent on a global basis [1] [2] [3] and are 2 of the most important cardiovascular risk factors. [4] [5] [6] [7] [8] Both entities are strongly correlated, 9 and the combined occurrence substantially increases cardiovascular risk in affected individuals. 10, 11 Although various factors, including hyperinsulinemia, volume expansion, and increased arterial stiffness, have been linked to elevated BP among diabetics, 12 mechanisms that predispose to the development of both dysglycemia and hypertension remain controversial and incompletely understood. 13 The incretin hormone glucagon-like peptide-1 (GLP-1) mediates its main effects by GLP-1 receptors (GLP-1R), which are found ubiquitously in the cardiovascular and renal system, including smooth muscle and endothelial cells. [14] [15] [16] [17] The main effects of GLP-1, the regulation of gastric emptying, and improvement of insulin sensitivity 18, 19 gave rise to a new antidiabetic drug class, the GLP-1R agonists (GLP-1RA). Recent studies suggest BP-lowering effects of GLP-1RA. [20] [21] [22] [23] In contrast, some [24] [25] [26] but not all 16 experimental studies showed a rise in BP after GLP-1 injection.
Thus, the GLP-1 system may provide a link between insulin resistance and elevated BP. In addition, because the use of GLP-1RA is strongly increasing and recommended by current guidelines, 27 further elucidation of the relationship between GLP-1 and BP is of major importance. The availability of a novel assay to measure GLP-1 levels easily and accurately in large samples provides the opportunity to get further insights on this timely issue. Therefore, we assessed the inter-relationships between various BP indices and fasting GLP-1 levels in a large sample of well-characterized healthy adults.
has been published previously. 28 Since 2010, all inhabitants of the Principality of Liechtenstein aged between 25 and 41 years have been enrolled into a prospective cohort study. Main exclusion criteria were current intake of antidiabetic drugs, a body mass index (BMI) >35 kg/m 2 , established cardiovascular disease, or any other severe illness. For the present analysis, we also excluded participants with invalid 24-hour BP measurements as defined below (n=90) and those currently using BP-lowering treatment (n=30), leaving 1479 subjects with available GLP-1 measurements. The study protocol was approved by the local ethics committee, and informed written consent was obtained from each participant.
BP Assessment
Ambulatory BP measurements were obtained using a validated automatic device (BR-102 plus; Schiller AG, Switzerland). 28 BP measurements were performed every 15 minutes from 07:30 to 22:00 and every 30 minutes in the remaining time period. Individual diaries were used to define awake and asleep BP values. If individuals had <80% of valid BP measurements, the recording was repeated if possible. For the purpose of this analysis, we included only participants with ≥10 valid awake and 5 valid asleep BP measurements. Conventional BP assessment was performed after 5 minutes of rest with 3 consecutive BP measurements using a validated oscillometric device (Microlife BP3AG1; Microlife AG, Switzerland). 28 The mean of the second and third reading was used for our analysis.
Assessment of Other Study Variables
Standardized questionnaires were used to assess personal, medical, lifestyle, and nutritional factors. Physical activity was assessed with the validated individual physical activity questionnaire. For the current project, we used physical activity as a continuous variable. Body composition was assessed by bioelectrical impedance analysis using a validated device (BIA ego fit, 2010, Germany). 28 Smoking status was graded as current, past, or never by self-assessment of the participants. Weight and height were directly measured in a standardized manner. BMI was calculated as body weight in kilogram divided by height in meters squared.
Blood Samples
Fasting venous blood samples were drawn from each participant and immediately stored at −80°C after centrifugation. GLP-1 was assayed from frozen EDTA plasma samples using a novel high-sensitive and single-molecule counting technology assay (Erenna Immunoassay System; Singulex, Alameda, CA). 29 Assessment of all other biomarkers used for the current analysis has been described in detail previously. 28 Homeostasis model assessment (HOMA) was calculated using the formula for HOMA-insulin resistance (HOMA-IR) by Matthews et al, 31 whereas an index value ≥2.0 was interpreted as indicating prevalent insulin resistance. For the assessment of the glomerular filtration rate, we used the creatinine-based chronic kidney disease epidemiology collaboration formula.
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Statistical Analysis
GLP-1 quartiles were used to stratify baseline characteristics. All continuous data were presented as mean or median (interquartile range) and compared using ANOVA or Kruskal-Wallis tests as appropriate, whereas categorical variables were presented as counts (percentages) and compared using χ 2 tests. To differentiate continuous versus noncontinuous associations across individual quartiles further, we performed Dunn's tests for those variables with significant P values on Kruskal-Wallis tests.
To compare the β-coefficients and 95% confidence intervals of 24-hour, awake, asleep, and conventional BP measurements across GLP-1 quartiles, we constructed multivariable linear regression models. Age-and sex-adjusted models were further adjusted for a predefined set of covariates, including BMI, high-sensitivity C-reactive protein, physical activity, low-density lipoprotein, high-density lipoprotein, N-terminal pro-brain natriuretic peptide, glomerular filtration rate, hemoglobin A 1c , smoking status, alcohol, fruits/vegetables and meat/ cold cut, body composition, and education status. Fruits/vegetables and meat/cold cut were used as binary variables. To test the hypothesis, that part of the associations may be explained by insulin resistance, the multivariable models were additionally adjusted for HOMA-IR index. Because all observed relationships were approximately linear, we performed additional analyses using GLP-1 as a log-transformed continuous variable. Prespecified subgroup analyses included multivariable regression models stratified by age, sex, BMI, prediabetes mellitus, dyslipidemia, current smoking, and HOMA-IR. Differences across subgroups were investigated by multiplicative interaction terms in the nonstratified models. All statistical analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC), and a value of P<0.05 was prespecified to indicate statistical significance.
Results
Baseline characteristics are displayed in Table 1 *Glucagon-like peptide-1 (GLP-1) was log-transformed. †P for trend across quartiles GLP-1. ‡Coefficients were adjusted for sex, age, body mass index, high-sensitivity C-reactive protein, physical activity, low-density lipoprotein, high-density lipoprotein, N-terminal pro-brain natriuretic peptide, glomerular filtration rate, hemoglobin A1c, smoking status, alcohol, fruit/vegetable, meat/cold cut, body composition, and education.
§Coefficients were additionally adjusted for continuous homeostatic model assessment insulin resistance.
After adjustment for a wide range of potential confounders, significant and approximately linear BP differences across GLP-1 quartiles persisted for all BP indices, as shown in Table 2 . In analyses using GLP-1 as a continuous variable, fully adjusted β coefficients (95% confidence interval) per 1-U increase in log-transformed GLP-1 were 2.01 (1.02-3.00; P≤0.0001) for 24-hour systolic BP, 2.05 (1.02; 3.09, P=0.0001) for awake systolic BP, 1.34 (0.26; 2.42, P=0.01) for asleep systolic BP and 1.06 (-0.11; 2.22, P=0.07) for conventional systolic BP, respectively. The corresponding β coefficients for diastolic BP were 1. Table 2 .
Subgroup analyses for 24-hour systolic BP revealed consistent results across all strata assessed, as shown in Table 3 . The observed association was somewhat stronger for men compared with women, the P value for interaction was of borderline significance (P=0.05). None of the other subgroup by GLP-1 interaction terms were statistically significant.
Discussion
To our knowledge, this is the first large, population-based study to assess the relationship between fasting GLP-1 levels and ambulatory BP indices. We believe that several new and potentially relevant findings emerged from this study.
First, we found that plasma levels of fasting GLP-1 are strongly and positively related to all BP indices assessed. This robust relationship was maintained in our multivariable models, showing that GLP-1 is associated both with awake and asleep BP. The only previous study investigating the relationship of GLP-1 with BP did not find a significant relationship, which could potentially be explained by the relatively small sample size of 128 study subjects and the absence of ambulatory BP measurement in the earlier study. 33 Other previous studies have mainly assessed the effect of GLP-1 RA or infusions on BP. Some of these studies found a reduction in BP levels with these interventions. 16, [20] [21] [22] [23] A possible explanation of our findings in this context could be a compensatory elevation of GLP-1 as a response to individual BP elevations, given the vasodilatory properties of GLP-1, 34, 35 the presence of endothelial dysfunction, 36 and renin-angiotensin system activation among individuals with elevated BP and the presence of GLP-1 receptors throughout the endothelial system.
14 Previous studies have indeed shown an improvement of endothelial function after the administration of GLP-1. 34, 35 However, if this hypothesis was true, the compensatory rise of GLP-1 in affected individuals would be ineffective or insufficient because complete compensation should have abolished the relationship between GLP-1 levels and BP in our study.
Second, adding HOMA as a measure of insulin resistance to our multivariable models attenuated the relationships between BP and GLP-1. These findings suggest that the relationships between insulin resistance and BP might be, in part, explained by GLP-1-related pathways, such that insulin resistance could be an ascending proxy for this association. Alternatively, microvascular endothelial dysfunction may cause insulin resistance, 37 high BP, 36, 38 and increases in GLP-1 levels, making insulin resistance a proxy for these interrelationships. This hypothesis is also supported by our finding that the associations between GLP-1 and BP were still statistically significant after adjustment for both HOMA, representing insulin resistance and hemoglobin A 1c representing long-term blood glucose levels, pointing toward a noninsulin-and nonglucosedependent link between GLP-1 and BP.
Strengths and Limitations
Strengths of our study include its population-based design and the availability of a large and well-defined cohort. The exclusion of individuals with treated hypertension, overt diabetes mellitus or cardiovascular disease minimizes the possibility of confounding by comorbidities. The availability of standardized 24-hour BP monitoring in all participants allowed us to assess separately awake and asleep BP. There are also limitations that have to be taken into account when interpreting our findings. First, the cross-sectional design does not allow to draw causal inference or to assess the directionality of the The β (95% confidence intervals) represents the increase in log-transformed glucagon-like peptide-1 U per change of 1 mm Hg of blood pressure. Coefficients were adjusted for sex, age, body mass index, high-sensitivity C-reactive protein, physical activity, low-density lipoprotein, high-density lipoprotein, N-terminal pro-brain natriuretic peptide, glomerular filtration rate, hemoglobin A1c, smoking status, alcohol, fruit/vegetable, meat/cold cut, body composition, and education as appropriate. n=1415, except prediabetes mellitus (n=1406) because of exclusion of diabetic patients. BMI indicates body mass index; and CI, confidence interval. by guest on April 19, 2017 http://hyper.ahajournals.org/ Downloaded from observed effects. Second, the great majority of the study population was white, and the generalizability of our results to other populations is uncertain. Third, we investigated GLP-1 levels after an overnight fast. We were, therefore, unable to investigate the relationships of BP with postprandial GLP-1 levels or with GLP-1 changes over time.
Perspectives
Fasting plasma levels of GLP-1 were significantly related to systolic and diastolic BP in a large cohort of young and healthy adults. These findings were consistent throughout all measured BP indices and were independent of a large number of potential confounders. Our results, therefore, suggest that the GLP-1 pathway may be implicated in human BP regulation and that insulin resistance may be involved in this relationship. Additional studies are needed to gain more insights in this important relationship.
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